Reviewing the inter partes review

The establishment of the US Patent Trial and Appeal Board (PTAB) in 2012 changed the game for patent owners. And while life science patents have not always been under the spotlight, recent trends suggest more such patents are being reviewed than ever before.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Careers

White & Case life sciences co-leader moves firms

2 September 2026 The senior transactions specialist brings experience advising pharmaceutical, biotechnology and technology companies on strategic alliances, licensing, M&A and cross-border transactions.

Careers

‘Busiest’ US district patent judge swaps bench for private practice

2 September 2026 One of the country's most prominent patent judges has joined A&O Shearman after nearly eight years on the federal bench.

Biotech

Exelixis locks down cancer drug exclusivity until 2030 with Fed Circ win

1 September 2026 Judges dismissed an appeal from MSN Laboratories, which was hoping to show that several patents covering Cabometyx were invalid and would not be infringed by its generic product.

More features

White & Case life sciences co-leader moves firms

‘Busiest’ US district patent judge swaps bench for private practice

Exelixis locks down cancer drug exclusivity until 2030 with Fed Circ win

Pinsents expands German patent practice with partner duo

Tempus AI bid to derail DNA patent case hits snag

Top law firms and individuals recognised in WIPR’s UK Patent Rankings 2026

Teva faces scrutiny over efforts to curb generic competition

FDA targets faster generic approvals in drive to slash drug prices

Reviewing the inter partes review

More on this story

Editor's picks

Editor's picks

More features